Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery

2016; Elsevier BV; Volume: 67; Issue: 3 Linguagem: Inglês

10.1016/j.jacc.2015.10.071

ISSN

1558-3597

Autores

Barbara E. Stähli, Jean‐Claude Tardif, Michel Carrier, Richard L. Gallo, Robert W. Emery, Stephen Robb, Daniel Cournoyer, Lucie Blondeau, Dominique Johnson, Jessica Mann, Jacques Lespérance, Marie‐Claude Guertin, Philippe L. L’Allier,

Tópico(s)

Coronary Interventions and Diagnostics

Resumo

Despite unprecedented advances over the last few decades, saphenous vein graft (SVG) failure remains a major concern following coronary artery bypass graft (CABG) surgery [(1)][1], and since contemporary treatment options are limited in these patients, there is an unmet need for novel therapeutic

Referência(s)